Tax Season is Here! Save 15% on H&R Block Online
iconAll times are GMT -4. The time now is 04:33 PM. | Search:

» StockRants Stock Forum » Public Stock Forums » Canadian Stock Picks » Strong Buy: (NRI) Price: 0.065 // 3 Approved drugs + FDA decision on March 4 = 500%++ Potential



Reply
 
Thread Tools Search this Thread
Old 01-15-2013, 10:05 AM   Nav to Top  #1
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 294
Favorites: Aapl celg onxx
Rep Power: 115
Reputation: 36
Biohero is on a distinguished road
Default (NRI) Price: 0.065 // 3 Approved drugs + FDA decision on March 4 = 500%++ Potential

You can buy this undiscovered BIG Goldmine currently at almost all time low .This is what is called a once in a lifetime opportunity .GLTA

FDA approval for Pennsaid (A Best in Class topical medication for osteoarthritis) on March 4 ,2013 . Pennsaid®: topical NSAID for osteoarthritis, partnered with Covidien for U.S., targeting $8B oral NSAID market

Nuvo will hit profitability this year with 2 new product launches in 2Q 2013 .Annual Revenue already hits $30 M .Nasdaq Listing is planned for this year which will bring more attention to this Goldmine .

A REAL 10 BAGGER HERE ...GLTA

Nuvo Research (NRI.TO)

Marktkap : $ 36 M
Cash: $ 12 M
Kurs: 0.065 $


New Presentation jan 2013
http://www.nuvoresearch.com/investor...nuary_2013.pdf


Massive Insider Activity
http://canadianinsider.com/node/7?menu_tickersearch=nri



 Growing revenue with 3 approved pain products:

 Pennsaid®: topical NSAID for osteoarthritis, partnered with Covidien for
U.S., targeting $8B oral NSAID market

 Pliaglis®: analgesic peelable cream, targeting global cosmetic and
dermatology markets, partnered with Galderma, worldwide launch
commencing Q2 2013

......

PropThink: Nuvo Research Gaining visibility; New Patent for Pennsaid 2% is Positive

Nuvo Research Inc. (TSX:NRI) announced that it obtained an additional U.S. patent for Pennsaid 2%, an improved follow-on formulation of its currently marketed Pennsaid product. Pennsaid contains the anti-inflammatory drug diclofenac, which is applied on the skin for pain conditions such as osteoarthritis of the knee. Pennsaid is currently marketed by Covidien's (NYSE:COV) pharmaceutical division Mallinkrodt, and Pennsaid 2% is undergoing FDA review for approval. The new version is a higher strength version of the product, and is formulated to increase the penetration of diclofenac through the skin to the site of pain. Importantly, the new formulation, if approved, will have patent protection out to 2028, and could become an important product for Covidien's pharmaceutical division, which is expected to be spun out to COV shareholders as a pure-play company in mid-2013. In July, Nuvo and Covidien announced that the FDA had accepted their New Drug Application (NDA) for Pennsaid 2% with a PDUFA (FDA action) date of March 4, 2013. Covidien stated that once Pennsaid 2% is approved, it expects to have the new patent listed in the FDA's Orange Book.

NRI shares remain on the radar screen, but could gain visibility on its portfolio of products for the topical treatment of pain. In addition to Covidien, the company is partnered with leading dermatology company Galderma, which is gearing up for approval and launch of Pliaglis. Pliaglis is Nuvo's topical anesthetic cream that will be marketed by Galderma for the reduction of pain associated with dermatological procedures. Several European countries have already notified Galderma that Pliaglis has been approved, and Galderma has responded to a Complete Response Letter (CRL) in the U.S. for potential FDA approval. Nuvo is also re-launching its Synera product, a topical anesthetic patch approved in the U.S. to provide pain relief for superficial dermatological procedures, and the company may seek to partner the drug in major markets. With only a $36 million market cap, shares of Nuvo Research have substantial room to run as U.S. investors become more familiar with the company.
Biohero is offline   Rate this post Yes | No Reply With Quote
Reply

Similar Threads
Thread Thread Starter Forum Replies Last Post
Strong Buy: SUPN = 2x MEGA DRUGS APPROVED // 1x BLOCKBUSTER IN P3 // LOW FLOAT 5 M = 500%++ POTEN Biohero US Stock Picks 0 12-03-2012 08:50 AM
Strong Buy: (HEB) (Price: $0.65) FDA approval for Blockbuster Drug within 2 months =500%++ Biohero US Penny Stock Picks 0 10-31-2012 07:06 AM
Strong Buy: (DND.T) FDA decision on 29 May /Mcap 24 M =1000% Potential ! Biohero Canadian Stock Picks 0 01-24-2012 08:02 AM
Strong Buy: 5 Drugs under review by FDA (Mcap 47 M )= MULTIBAGGER biotechmaster US Stock Picks 13 07-26-2011 10:59 AM
Dividend: $UVFT kills Swine Flu, FDA approved products!!!! $$ monsterpennies US Penny Stock Picks 0 12-24-2009 02:05 PM


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On